Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LYC-55716 |
Synonyms | |
Therapy Description |
Cintirorgon (LYC-55716) is a retinoic acid-related orphan receptor gamma agonist, which may increase T-cell mediated anti-tumor immune response, potentially leading to inhibition of tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5566, PMID: 30819679). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LYC-55716 | Cintirorgon|LYC55716 | Cintirorgon (LYC-55716) is a retinoic acid-related orphan receptor gamma agonist, which may increase T-cell mediated anti-tumor immune response, potentially leading to inhibition of tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5566, PMID: 30819679). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02929862 | Phase Ib/II | LYC-55716 | Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer | Completed | USA | 0 |